These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11523556)

  • 21. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketolides: the future of the macrolides?
    Nilius AM; Ma Z
    Curr Opin Pharmacol; 2002 Oct; 2(5):493-500. PubMed ID: 12324249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.
    Ma CX; Lv W; Li YX; Fan BZ; Han X; Kong FS; Tian JC; Cushman M; Liang JH
    Eur J Med Chem; 2019 May; 169():1-20. PubMed ID: 30852383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM; Dever LL
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketolides in the treatment of respiratory infections.
    Zhanel GG; Hoban DJ
    Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Investigation of macrolide-lincosamide-streptogramin B (MLS(B)) and telithromycin resistance in clinical strains of staphylococci].
    Saribaş Z; Tunçkanat F; Ozçakir O; Ercis S
    Mikrobiyol Bul; 2010 Apr; 44(2):177-86. PubMed ID: 20549951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nature nurtures the design of new semi-synthetic macrolide antibiotics.
    Fernandes P; Martens E; Pereira D
    J Antibiot (Tokyo); 2017 May; 70(5):527-533. PubMed ID: 27899792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Macrolides, ketolides and streptogramins].
    Mensa J; García-Vázquez E; Vila J
    Enferm Infecc Microbiol Clin; 2003 Apr; 21(4):200-7; quiz 208, 219. PubMed ID: 12681133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide and ketolide resistance with Streptococcus pneumoniae.
    Doern GV
    Med Clin North Am; 2006 Nov; 90(6):1109-24. PubMed ID: 17116439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
    Agouridas C; Denis A; Auger JM; Benedetti Y; Bonnefoy A; Bretin F; Chantot JF; Dussarat A; Fromentin C; D'Ambrières SG; Lachaud S; Laurin P; Le Martret O; Loyau V; Tessot N
    J Med Chem; 1998 Oct; 41(21):4080-100. PubMed ID: 9767644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.
    Novotny GW; Jakobsen L; Andersen NM; Poehlsgaard J; Douthwaite S
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3677-83. PubMed ID: 15388419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT; Neuhauser MM; Garey KW
    Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telithromycin.
    Balfour JA; Figgitt DP
    Drugs; 2001; 61(6):815-29; discussion 830-1. PubMed ID: 11398913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells.
    Champney WS; Pelt J
    Curr Microbiol; 2002 Sep; 45(3):155-60. PubMed ID: 12177734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.